C-13-60

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameC-13-60
Drug Alias NameTargeting CEA Chimeric Antigen Receptor T (CAR-T)therapy(Precision Biotechnology)Chimeric Antigen Receptor T Cells (C-13-60) therapy(Precision Biotechnology)CEA-targeted CAR-T cells therapy(Precision Biotechnology)C-13-60
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CEA
TargetsCarcinoembryonic antigen
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[9] 
Inactive IndicationsSolid tumoursLung NeoplasmsLiver Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A